The Theme Code "他の有機化合物及び無機化合物含有医薬技術" had 1,778 patent application filings in the most recent period (2022-01-01 to 2022-07-31). This is a significantly decreased of -1,547 filings (-46.5%) over 3,325 they had in the same period of the previous year (2021-01-01 to 2021-07-31).
The company had their highest number of filings in 2017 with 7,738 cases, and their lowest number in 2022 with 2,032 cases.
The mean of the number of filings over the last 5 years (2018 to 2023, 27,638 cases in total) is 4,606, and the median is 5,696. The coefficient of variation (standard deviation/mean) is 0.6, and there have been big fluctuations in the number of filings from year to year.
Index | Value |
---|---|
Average | 4,606 patents |
Std Dev | 2,604 |
COV | 0.6 |
Year | Cases | YOY |
---|---|---|
2022 year | 2,032 cases | -63.1 % |
2021 year | 5,508 cases | -6.39 % |
2020 year | 5,884 cases | -12.22 % |
This report provides the latest patent analysis information (the IP landscape, including a patent map) on the patent search results of the JP patent database for 他の有機化合物及び無機化合物含有医薬技術[4C086] for the period of the last 10 years (2014-01-01 to 2024-03-31). You can compare the information in this report with the trends in your competitors’ patent filings and technologies, and use it to search for important patents.
This service provides, free of charge, a patent analysis report based on the latest patent data (Japanese, U.S., European, and PCT application publications) for use in patent searches, patent analysis, and IP landscaping. The service is offered by "Patent Integration" a firm specializing in patent search/patent analysis.
This report includes basic information to help you understand the IP strategy and management of 他の有機化合物及び無機化合物含有医薬技術, such as changes in the number of patents/patent applications they have filed, comparisons of the numbers of patents/patent applications filed by their peers and competitors, their top coapplicants (joint research partners, alliance partners), and their most important patents. It can be used in various intellectual property business operations such as IP landscaping, patent search/patent analysis, preparation of intellectual property business evaluation reports, selection of M&A candidates, and selection of alliance partners.
He is a patent attorney at a patent office. He specializes in invention counseling, patent filing, and intellectual property strategies for start-up companies and new businesses in the fields of software, information technology and artificial intelligence. He runs a patent course for beginners on Udemy, an online course provider.
After studying physics at the University of Tokyo as a doctoral student, he was engaged in intellectual property analysis and technology trend research as an in-house patent attorney at a precision equipment manufacturer and at Toyota Central R&D Labs. Inc..
The concept of the "IP landscape" (IPL) has been attracting attention recently.
An IP landscape is not limited to patent information, but also integrates and analyzes business information (e.g., non-patent information such as papers, news releases, stock information, and market information). Intellectual-property-based business management is realized through the analysis of intellectual property information applied to the formulation of management strategies and business strategies. This is a comprehensive approach that includes but not limited to planning of open and closed strategies, selecting M&A candidates, searching for alliance partners, and formulating intellectual property strategies, through the exploitation of intellectual property information.
IP landscaping usually includes patent search and patent analysis. In patent search and patent analysis, it is important to grasp the market position of each company and the overall technological trends and development trends for each technology. More specifically, it is important to understand what intellectual property your own company and other companies hold, what the strengths and weaknesses of other companies are, and how other companies are trying to exploit their intellectual property. In other words, it is important to understand both the business strategy and the intellectual property strategy of each company.
After reading this search report, you may be interested in more detailed patent searches and patent analysis. We offer a service called Patent Integration, which is an integrated patent search and patent analysis service. With reasonable pricing and a simple user interface such that even beginners can quickly search for and analyze patent information by company or technology from a web browser, please consider using it for detailed patent searches, patent analysis, and IP landscaping.
Patent Integration has a patent-landscaping function that can visually represent a set of tens of thousands of patents/patent applications. This allows you to convincingly show the technical positions of your company and its competitors to your management and business strategists in order to formulate management strategies and business strategies.
The changes in the number of patent filings of 他の有機化合物及び無機化合物含有医薬技術 over the last 20 years (JP) are shown below.
The change in the number of patents/patent applications is the most basic index in patent analysis. By examining the change in the number of patents/patent applications, you can see the status of technological development and R&D focus for each company or technology. It should be noted that since there is a one and a half year lag between the filing and the laying open of patent applications, it is not possible to analyze the situation more recently than one and half years prior to the present.
In this report, you can only see the change in the number of patents/patent applications by company or technology, whereas Patent Integration allows you to quickly compare the number of patent applications with your competitors in each technical field by cross-referencing with other keywords and patent classifications.
Patent landscaping is a visualization of the distribution of patent filings (application focus areas) for each technical keyword. Mountains and islands indicated by heatmap contours represent clusters of patent applications filed, and red areas on the heatmap indicate many patent filings relating to the keyword.
The patent landscape for 他の有機化合物及び無機化合物含有医薬技術 gives an intuitive understanding of what patent filings they have made and what technical position is to be established. By selecting filing year checkboxes and filtering, you can track their past filing trends (what technical area they have focused on).
By selecting applicant/patent holder checkboxes and filtering, you can visually grasp the technical areas of the filings for each applicant and the partnerships or alliances formed. Please use it as a guide for patent analysis and IP landscaping.
In addition, by visually representing the patent data in this manner, you can convincingly show the technical positions of your company and its competitors to your management and business strategists in order to formulate management strategies and business strategies.
In Patent Integration, you can check the specifics of a patent filing by clicking anywhere on the patent landscape screen. You can also quickly check the position of each applicant for each technical field by cross-referencing with other keywords and patent classifications. You can use it as a guide when considering hypotheses about each company's IP strategy on the IP Landscape. You can also use it for higher-grade intellectual property activities. It has reasonable pricing and a simple user interface that is easy for beginners to handle.
The following is a list of words (characteristic terms) often used in 他の有機化合物及び無機化合物含有医薬技術 patent applications. Characteristic terms with a higher importance are used in more patents/patent applications.
This patent analysis report was created for a patent search set of 57,325 cases retrieved by applying the following search formula and analysis period to the following patent database. Patent information such as a patent analysis result, a patent map, and a patent landscape can be freely used for patent searches, analysis, and work on intellectual property strategies, including IP landscaping.
The patent information of the higher applicant in the technical theme 他の有機化合物及び無機化合物含有医薬技術 is shown below. By comparing the number of patents of each company, you can check the research and development status of each company's past and present technical themes and the position of each company in the technical theme.
Comparing the number of applications of each company, 大正製薬株式会社 has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 22 cases, followed by ノバルティスアーゲー with 20 cases.
Name | Cases |
---|---|
大正製薬株式会社 | 22 cases |
ノバルティスアーゲー | 20 cases |
ブリストル-マイヤーズスクイブカンパニー | 11 cases |
ヤンセンファーマシューティカエヌベー | 10 cases |
武田薬品工業株式会社 | 9 cases |
ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 9 cases |
エフホフマン-ラロシュアーゲー | 8 cases |
アステラス製薬株式会社 | 6 cases |
アストラゼネカ・アクチエボラーグ | 6 cases |
Comparing the number of applications of each company, ノバルティスアーゲー has the highest number of joint applications in the last for the target period (2014 to 2024) with 826 cases, followed by エフホフマン-ラロシュアーゲー with 576 cases.
Name | Cases |
---|---|
ノバルティスアーゲー | 826 cases |
エフホフマン-ラロシュアーゲー | 576 cases |
ブリストル-マイヤーズスクイブカンパニー | 452 cases |
ヤンセンファーマシューティカエヌベー | 339 cases |
ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 336 cases |
武田薬品工業株式会社 | 322 cases |
大正製薬株式会社 | 232 cases |
アストラゼネカ・アクチエボラーグ | 170 cases |
メルク・シャープ・アンド・ドーム・コーポレーション | 144 cases |
アステラス製薬株式会社 | 83 cases |
メルク・シャープ・エンド・ドーム・コーポレイション | 2 cases |
Below is a patent map showing changes in the number of applications for JP patents of 11 companies in the same industry over the past 20 years.
The patent information of the higher applicant in the technical theme 他の有機化合物及び無機化合物含有医薬技術 is shown below. By comparing the number of patents of each company, you can check the research and development status of each company's past and present technical themes and the position of each company in the technical theme.
among the top coapplicants, 大正製薬株式会社 has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 22 cases, followed by ノバルティスアーゲー with 20 cases.
Name | Cases |
---|---|
大正製薬株式会社 | 22 cases |
ノバルティスアーゲー | 20 cases |
武田薬品工業株式会社 | 9 cases |
ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 9 cases |
エフホフマン-ラロシュアーゲー | 8 cases |
アステラス製薬株式会社 | 6 cases |
among the top coapplicants, ノバルティスアーゲー has the highest number of joint applications in the last for the target period (2014 to 2024) with 826 cases, followed by エフホフマン-ラロシュアーゲー with 576 cases.
Name | Cases |
---|---|
ノバルティスアーゲー | 826 cases |
エフホフマン-ラロシュアーゲー | 576 cases |
ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 336 cases |
武田薬品工業株式会社 | 322 cases |
大正製薬株式会社 | 232 cases |
アステラス製薬株式会社 | 83 cases |
メルク・シャープ・エンド・ドーム・コーポレイション | 2 cases |
Below is a patent map showing the changes in the numbers of JP patent filings by 他の有機化合物及び無機化合物含有医薬技術’s top 7 coapplicants over the last 20 years.
他の有機化合物及び無機化合物含有医薬技術 filed 826 joint applications with ノバルティスアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 351 cases in total) is 58.5, and the median is 65.5. The coefficient of variation (standard deviation/mean) is 0.7, and there have been relatively large fluctuations in the number of filings from year to year.
The company had their highest number of filings in 2014 with 140 cases, and their lowest number in 2022 with 19 cases.
Index | Value |
---|---|
Average | 58.5 patents |
Std Dev | 38.8 |
COV | 0.7 |
Year | Cases | YOY |
---|---|---|
2022 year | 19 cases | -63.5 % |
2021 year | 52 cases | -34.2 % |
2020 year | 79 cases | -11.24 % |
他の有機化合物及び無機化合物含有医薬技術 filed 322 joint applications with 武田薬品工業株式会社 for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 136 cases in total) is 22.7, and the median is 20.5. The coefficient of variation (standard deviation/mean) is 0.7, and there have been relatively large fluctuations in the number of filings from year to year.
The company had their highest number of filings in 2015 with 56 cases, and their lowest number in 2022 with 9 cases.
Index | Value |
---|---|
Average | 22.7 patents |
Std Dev | 16.4 |
COV | 0.7 |
Year | Cases | YOY |
---|---|---|
2022 year | 9 cases | -43.8 % |
2021 year | 16 cases | -36.0 % |
2020 year | 25 cases | -35.9 % |
他の有機化合物及び無機化合物含有医薬技術 filed 576 joint applications with エフホフマン-ラロシュアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 246 cases in total) is 41.0, and the median is 52.5. The coefficient of variation (standard deviation/mean) is 0.7, and there have been relatively large fluctuations in the number of filings from year to year.
The company had their highest number of filings in 2014 with 97 cases, and their lowest number in 2022 with 8 cases.
Index | Value |
---|---|
Average | 41.0 patents |
Std Dev | 26.9 |
COV | 0.7 |
Year | Cases | YOY |
---|---|---|
2022 year | 8 cases | -84.6 % |
2021 year | 52 cases | -1.89 % |
2020 year | 53 cases | -23.19 % |
他の有機化合物及び無機化合物含有医薬技術 filed 232 joint applications with 大正製薬株式会社 for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 95 cases in total) is 15.8, and the median is 16.5. The coefficient of variation (standard deviation/mean) is 0.4, and there have been big fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The company had their highest number of filings in 2017 with 41 cases, and their lowest number in 2019 with 11 cases.
Index | Value |
---|---|
Average | 15.8 patents |
Std Dev | 7.0 |
COV | 0.4 |
Year | Cases | YOY |
---|---|---|
2022 year | 17 cases | -39.3 % |
2021 year | 28 cases | +55.6 % |
2020 year | 18 cases | +63.6 % |
他の有機化合物及び無機化合物含有医薬技術 filed 83 joint applications with アステラス製薬株式会社 for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 27 cases in total) is 4.5, and the median is 4.0. The coefficient of variation (standard deviation/mean) is 0.6, and there have been relatively large fluctuations in the number of filings from year to year.
The number of filings has been increasing for the last 3 years (2020 to 2023). The company had their highest number of filings in 2015 with 23 cases, and their lowest number in 2020 with 2 cases.
Index | Value |
---|---|
Average | 4.5 patents |
Std Dev | 2.8 |
COV | 0.6 |
Year | Cases | YOY |
---|---|---|
2022 year | 5 cases | +66.7 % |
2021 year | 3 cases | +50.0 % |
2020 year | 2 cases | -75.0 % |
The following shows JP patents held by 他の有機化合物及び無機化合物含有医薬技術 that have had an invalidation trial against them demanded or an opposition filed against them by a third party, and 他の有機化合物及び無機化合物含有医薬技術’s JP patents/patent applications of high importance cited by Examiners in patent examination processes.
By noting the most important patents, you can obtain knowledge of the competitive business environment in which 他の有機化合物及び無機化合物含有医薬技術 is placed (e.g., whether it is a fiercely competitive environment or an oligopolistic market and the like). In general, it can be understood that a company with a large number of demands for invalidation trials is developing their business in a business environment where IP disputes are common.
If you want to search for more detailed information, you can use Patent Integration to retrieve and download by company cited patents/patent applications or patents undergoing invalidation trials. You can quickly extract important patents from a patent set that includes multiple competitors by cross-referencing with other keywords and patent classifications. Please consider using it for searches for important patents/patent applications.
In the last 3 years (2021-04-01 ~ 2024-03-31), there were 32 patents Invalidation Trial from third parties. The average number of Invalidation Trial is 1.5 times. The most recently Invalidation Trial patent is 特許6262023 "経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療" (Invalidation Trial day 2024-01-31) , next is 特許6189374 "糖尿病療法" (Invalidation Trial day 2024-01-31) .
- | No. | Title | Invalidation Trial days |
---|---|---|---|
1 | 特許6262023 | 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療 | 2024-01-31 |
2 | 特許6189374 | 糖尿病療法 | 2024-01-31 |
3 | 特許4332353 | 15−ケト−プロスタグランジン類を含む薬物誘発性便秘処置用組成物 | 2023-12-09 |
4 | 特許6445123 | 癌を治療するための方法及び組成物 | 2023-11-25 |
5 | 特許6740497 | 癌を治療するための方法及び組成物 | 2023-11-25 |
6 | 特許6290627 | メトホルミン治療に不適切な患者における糖尿病の治療 | 2023-09-07 |
7 | 特許6662970 | DPP IVインヒビターの使用 | 2023-09-04 |
8 | 特許4110140 | チロシンキナーゼの阻害剤 | 2023-08-10 |
9 | 特許7194153 | 新規製剤 | 2023-07-21 |
10 | 特許7185426 | S1P受容体モジュレーターの投与計画 | 2023-07-10 |
Of the patent applications filed in the last 10 years (2014-04-01 to 2024-03-31), 21 patents/patent applications were invalidation trial more than once in the examination process of other patent applications. The mean of the number of invalidation trial is 1.3. The most invalidation trial patent is 特許6445123 "癌を治療するための方法及び組成物" (5 times) , and the next most invalidation trial patent is 特許5906333 "プロタンパク質コンベルターゼスブチリシンケクシン9型(PCSK9)に対する抗原結合タンパク質" (2 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許6445123 | 癌を治療するための方法及び組成物 | 5 times |
2 | 特許5906333 | プロタンパク質コンベルターゼスブチリシンケクシン9型(PCSK9)に対する抗原結合タンパク質 | 2 times |
3 | 特許6198346 | 1回当たり100〜200単位のPTHが週1回投与されることを特徴とする、PTH含有骨粗鬆症治療/予防剤 | 2 times |
4 | 特許5910698 | リセドロネート組成物およびその使用方法 | 1 times |
5 | 特許6662970 | DPP IVインヒビターの使用 | 1 times |
In the last 3 years (2021-04-01 ~ 2024-03-31), there were 57 patents Opposition from third parties. The average number of Opposition is 1.0 times. The most recently Opposition patent is 特許7317256 "集中力及び/又は情報処理能力の向上剤" (Opposition day 2024-01-25) , next is 特許7282155 "頭皮用外用組成物" (Opposition day 2023-11-24) .
- | No. | Title | Opposition days |
---|---|---|---|
1 | 特許7317256 | 集中力及び/又は情報処理能力の向上剤 | 2024-01-25 |
2 | 特許7282155 | 頭皮用外用組成物 | 2023-11-24 |
3 | 特許7281031 | 加齢に伴う持続的注意力低下の改善用の組成物 | 2023-11-21 |
4 | 特許7270996 | 美容組成物 | 2023-11-10 |
5 | 特許7244922 | 化学修飾された一本鎖RNA編集オリゴヌクレオチド | 2023-09-20 |
6 | 特許7237544 | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 | 2023-09-11 |
7 | 特許7231197 | 医薬用錠剤 | 2023-08-29 |
8 | 特許7223501 | 経口組成物 | 2023-08-15 |
9 | 特許7188087 | 一本鎖オリゴヌクレオチド | 2023-06-12 |
10 | 特許7253126 | フェンタニル含有貼付剤 | 2023-06-08 |
In the last 3 years (2021-04-01 ~ 2024-03-31), there were 332 patents Protest from third parties. The average number of Protest is 1.8 times. The most recently Protest patent is 特表2021-527040 "カンプトテシンコンジュゲート" (Protest day 2024-03-25) , next is 特開2021-059520 "外用組成物" (Protest day 2024-03-22) .
- | No. | Title | Protest days |
---|---|---|---|
1 | 特表2021-527040 | カンプトテシンコンジュゲート | 2024-03-25 |
2 | 特開2021-059520 | 外用組成物 | 2024-03-22 |
3 | 特開2023-062563 | 栄養組成物 | 2024-03-19 |
4 | 特開2023-062564 | 組成物 | 2024-03-19 |
5 | 特開2023-022363 | 細胞保護用剤 | 2024-03-19 |
6 | 特表2023-519172 | 胃腸微生物代謝経路及び代謝物を調節する方法 | 2024-03-08 |
7 | 特開2022-076152 | 変色が抑制された経口組成物及びその変色抑制方法 | 2024-02-28 |
8 | 特開2021-014416 | 外用製剤 | 2024-02-27 |
9 | 特開2021-129533 | 経口用組成物 | 2024-02-26 |
10 | 特許7464243 | かゆみを伴う乾燥性皮膚の治療薬 | 2024-02-20 |
11 | 特開2023-166957 | 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法 | 2024-02-20 |
12 | 特開2022-076151 | 変色が抑制された経口組成物及びその変色抑制方法 | 2024-02-19 |
13 | 特開2022-047344 | におい感覚抑制剤 | 2024-02-17 |
14 | 特許7446003 | マカ抽出物及びその用途 | 2024-02-16 |
15 | 特開2022-173166 | エピナスチン含有点眼液 | 2024-02-15 |
16 | 特開2022-025713 | 紫外線暴露により誘発される皮膚障害の軽減又は抑制用経口組成物 | 2024-02-14 |
17 | 特開2023-029502 | 血流改善剤 | 2024-02-13 |
18 | 特表2023-509132 | 口内溶解性フィルムおよび口内溶解性フィルムを製造し、使用する方法 | 2024-02-13 |
19 | 特開2022-104234 | 口腔用組成物 | 2024-02-09 |
20 | 特表2023-534047 | オリゴ糖組成物及び使用方法 | 2024-02-07 |
Of the patent applications filed in the last 10 years (2014-04-01 to 2024-03-31), 639 patents/patent applications were protest more than once in the examination process of other patent applications. The mean of the number of protest is 1.6. The most protest patent is 特許7320919 "小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療" (10 times) , and the next most protest patent is 特開2018-048105 "外用組成物" (10 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許7320919 | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 | 10 times |
2 | 特開2018-048105 | 外用組成物 | 10 times |
3 | 特開2018-048104 | 外用組成物 | 9 times |
4 | 特開2019-123706 | 経口ゲル状組成物 | 8 times |
5 | 特許6210640 | ホリナートカルシウム含有錠 | 8 times |
In the last 3 years (2021-04-01 ~ 2024-03-31), there were 1,230 patents Inspection from third parties. The average number of Inspection is 2.1 times. The most recently Inspection patent is 特開2023-062563 "栄養組成物" (Inspection day 2024-03-26) , next is 特開2014-159381 "オルニチン含有体組成改善用組成物" (Inspection day 2024-03-26) .
- | No. | Title | Inspection days |
---|---|---|---|
1 | 特開2023-062563 | 栄養組成物 | 2024-03-26 |
2 | 特開2014-159381 | オルニチン含有体組成改善用組成物 | 2024-03-26 |
3 | 特開2023-062564 | 組成物 | 2024-03-26 |
4 | 特開2019-011372 | インターロイキン−6関連疾患の治療方法 | 2024-03-26 |
5 | 特許7467479 | 多発性骨髄腫の治療における抗増殖化合物及び第2の活性薬剤とそれらの併用方法 | 2024-03-22 |
6 | 特表2021-517140 | マイクロバイオームの均衡をとるのに使用するための組成物 | 2024-03-21 |
7 | 特表2020-536960 | シロシビン、異なる多形形態、中間体、調合物の調製及びそれらの使用 | 2024-03-19 |
8 | 特表2022-508807 | 腫瘍内注射製剤 | 2024-03-19 |
9 | 特表2023-525436 | ビグアニド系化合物、及びフラボン、ヒドロキシフラボン、フラバノン、フラボン誘導体、ヒドロキシフラボン誘導体、フラバノン誘導体の複合剤を有効成分として含有する癌の予防または治療用薬学的組成物 | 2024-03-18 |
10 | 特表2023-528059 | 抗ウイルス剤及び抗うつ剤を有効成分として含有する癌の予防または治療用薬学的組成物 | 2024-03-18 |
11 | 再公表2019/013234 | ビタミンB1類を配合する固形製剤 | 2024-03-18 |
12 | 特許5645183 | D−プシコースを有効成分として含む肥満状態改善剤 | 2024-03-13 |
13 | 特表2021-529821 | イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法 | 2024-03-13 |
14 | 特表2021-534146 | アセチル−COAカルボキシラーゼ2アンチセンスオリゴヌクレオチド | 2024-03-12 |
15 | 特表2023-509132 | 口内溶解性フィルムおよび口内溶解性フィルムを製造し、使用する方法 | 2024-03-11 |
16 | 特開2022-025713 | 紫外線暴露により誘発される皮膚障害の軽減又は抑制用経口組成物 | 2024-03-11 |
17 | 特開2022-126760 | 軟質複室バッグおよびその使用方法 | 2024-03-11 |
18 | 特許3763360 | 下痢型過敏性腸症候群治療剤 | 2024-03-11 |
19 | 特表2021-514394 | 止血材 | 2024-03-11 |
20 | 特開2021-014416 | 外用製剤 | 2024-03-08 |
Of the patent applications filed in the last 10 years (2014-04-01 to 2024-03-31), 2,166 patents/patent applications were inspection more than once in the examination process of other patent applications. The mean of the number of inspection is 1.7. The most inspection patent is 特開2017-149726 "B細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療" (46 times) , and the next most inspection patent is 特開2017-214435 "抗CD20抗体の投与を含むB細胞リンパ腫の併用療法" (43 times) .
- | No. | Title | |
---|---|---|---|
1 | 特開2017-149726 | B細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療 | 46 times |
2 | 特開2017-214435 | 抗CD20抗体の投与を含むB細胞リンパ腫の併用療法 | 43 times |
3 | 特開2018-048105 | 外用組成物 | 32 times |
4 | 特許6142892 | 経口投与用医薬組成物 | 30 times |
5 | 特許7376250 | 皮膚外用組成物 | 30 times |
Of the patent applications filed in the last 10 years (2014-04-01 to 2024-03-31), 8,494 patents/patent applications were cited more than once in the examination process of other patent applications. The mean of the number of cited is 2.1. The most cited patent is 特開2014-217381 "miRNAおよびmiRNA阻害分子に関する方法および組成物" (68 times) , and the next most cited patent is 特許6521977 "免疫調節剤としての1,2,4−オキサジアゾール誘導体" (39 times) .
- | No. | Title | |
---|---|---|---|
1 | 特開2014-217381 | miRNAおよびmiRNA阻害分子に関する方法および組成物 | 68 times |
2 | 特許6521977 | 免疫調節剤としての1,2,4−オキサジアゾール誘導体 | 39 times |
3 | 特許7078274 | ナノ構造体をコーティングするための化学化合物 | 33 times |
4 | 特開2017-104848 | シリコン微細ナノ粒子及び/又はその凝集体及び生体用水素発生材及びその製造方法並びに水素水とその製造方法及び製造装置 | 32 times |
5 | 特許5902237 | PSMA結合性リガンド−リンカー結合体及び使用方法 | 31 times |
"Patent Integration Report" is a web service provided by "Patent Integration Co., Ltd." operated by patent attorneys who are experts in intellectual property rights. Based on the latest patent data, this is one of the largest patent report services in Japan that provides information on technology trends in various companies and technology fields.
The purpose of this web service is to make intellectual property information familiar to many people, regardless of whether they have an interest in intellectual property rights, and to make use of it.
We actively provide various types of patent information that can be used in various media articles such as newspapers, magazines, and web media. Please feel free to contact us from "Inquiry form for details on the content of patent information that can be provided, conditions for provision, etc. Please contact us.
All rights related to the data, documents and charts belong to "an integrated patent search/analysis service provider, Patent Integration". Please specify the source “Patent Integration Report, URL: https://patent-i.com/report/en/" when inserting them into in-house materials, external report materials, etc., regardless of whether they are paid or free of charge.
Patent data is obtained by aggregating and analyzing the latest patent data issued by the Patent Offices of respective countries and jurisdictions and by WIPO. Although we take great care in publishing and analyzing the results, we do not guarantee the correctness of the data. We appreciate your understanding.
If you have any concerns about this service, please feel free to contact us.
Credit notation
・MeCab user dictionary for science technology term © National Bioscience Database Center licensed under CC Attribution-Share Alike 4.0 International